Skip to main content

Table 3 Prognostic parameters (PFS), Cox regression analysis

From: Are there candidates for high-dose chemotherapy in ovarian carcinoma?

A. Whole population
  Univariate analysis Multivariate analysis
  N HR 95CI p -value N HR 95CI p -value
Age (>50y vs ≤50y) 163 1.12 0.76-1.66 0.57     
OMS (0-1 vs 2-3) 117 1.53 0.88-2.67 0.14     
FIGO (IIIc vs IV) 163 0.7 0.45-1.08 0.1     
Histology (serous vs others) 163 0.95 0.66-1.39 0.8     
Grade (1-2 vs 3) 98 1.2 0.93-1.55 0.16     
Serous grade 3 (vs others) 98 1.42 0.80-2.52 0.23     
Surgery (complete vs non complete) 160 0.38 0.26-0.54 2.23 E-07 147 0.57 0.37-0.87 0.01
Complete clinical remission (Yes vs No) 161 0.33 0.23-0.49 2.14 E-08 147 0.55 0.33-0.92 0.02
CA-125 (normal vs >normal) 149 0.45 0.29-0.71 6.9 E-04 147 0.77 0.45-1.32 0.34
Time from end of initial CT to HDC    NA      
Treatment (CCA vs HDC) 163 1.39 0.95-2.03 0.09     
B. According to chemotheraphy regimen, univariate analysis
  Conventional CT High dose CT
  N HR 95CI p -value N HR 95CI p -value
Age (>50y vs ≤50y) 103 0.83 0.52-1.33 0.44 60 2.03 0.96-4.29 0.06
OMS (0-1 vs 2-3) 78 1.56 0.84-2.89 0.16 39 0.96 0.22-4.17 0.95
FIGO (IIIc vs IV) 103 0.93 0.52-1.70 0.82 60 0.4 0.20-0.78 0.007
Histology (serous vs others) 103 1.24 0.78-1.97 0.37 60 0.83 0.44-1.58 0.56
Grade (1-2 vs 3) 62 1.17 0.85-1.61 0.35 36 1.08 0.67-1.72 0.76
Serous grade 3 (vs others) 62 0.81 0.57-1.15 0.24 36 0.98 0.51-1.87 0.94
Surgery (complete vs non complete) 100 0.29 0.18-0.46 2.2 E-07 60 0.65 0.34-1.22 0.18
Complete clinical remission (Yes vs No) 101 0.32 0.20-0.51 1.78 E-06 60 0.44 0.20-0.97 0.04
CA-125 (normal vs >normal) 91 0.32 0.18-0.56 6.41 E-05 58 1.21 0.53 2.74
Time from end of initial CT to HDC    NA   60 0.97 0.86-1.09 0.59
Treatment (CCA vs HDC)    NA     NA  
  1. PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; HDC, high-dose chemotherapy; CCA, conventional chemotherapy alone.